Quince Therapeutics, Inc. · NASDAQ:QNCX
Quince Therapeutics — Merger or Acquisition (July 2023)
19 slides from Quince Therapeutics's merger presentation, Jul 24, 2023
Slide 1: Quince Therapeutics to Acquire EryDel
Exhibit 99.1 Quince Therapeutics to Acquire EryDel July 24, 2023
Slide 2: Forward-looking statements
Forward-looking statements Statements in this presentation contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
Slide 3: Transformative acquisition with value-creating clinical milestones
Transformative acquisition with value-creating clinical milestones Phase 3 lead asset EryDex targets Ataxia-Telangiectasia (A-T) with no currently approved treatments and estimated $1+ billion peak sales opportunity EryDex designed for controlled, slow release of dexamethasone over several weeks wit
Slide 4: EryDel significant achievements
EryDel significant achievements Headquarters • Bresso, Italy 20+ years of work on autologous intracellular drug encapsulation (AIDE) technology platform Manufacturing $100+ million invested since founding out of University of Urbino, Italy • Medolla, Italy EryDex designated as orphan drug for A-T tr
Slide 5: EryDel acquisition transaction details
EryDel acquisition transaction details Overview Stock-for-stock upfront exchange of Quince stock and potential downstream milestone cash payments of up to $485 million Unanimously approved by both companies’ Board of Directors • Up to $5 million in development milestones • $25 million at NDA accepta
Slide 6: Autologous intracellular drug encapsulation (AIDE) technology
Autologous intracellular drug encapsulation (AIDE) technology Unique drug/device combination enables automated process for autologous intracellular drug encapsulation Platform capable of expansion to other drugs or biologics, including enzyme replacement therapy 6
Slide 7: Fully automated autologous point-of-care treatment
Fully automated autologous point-of-care treatment Patient’s blood collected at the point-of-care for fully automated bedside procedure completed within two hours Bedside Blood Collection Erythrocytes loaded onto the Red Cell Loader using EryKit Erythrocytes swollen and pores opened via multiple ste
Slide 8: No currently approved treatments for A-T patients
No currently approved treatments for A-T patients A-T is an inherited neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene Approximately 10,000 A-T patients in U.S., U.K., and EU4 countries Neurological symptoms worsen until patients are wheelchair-bound, usually by adoles
Slide 9: EryDex efficacy and safety profile demonstrated in prior clinical trial
EryDex efficacy and safety profile EryDex ATTeST Trial demonstrated in prior clinical trial Completed largest global study of A-T patients in Phase 3 ATTeST clinical trial and OLE • Double-blind, placebo-controlled study (N=175) over 6-month treatment period with 12-month OLE (N=104) • Patients rand
Slide 10: EryDex treatment slows neurological deterioration in all ages of A-T patients
EryDex treatment slows neurological deterioration EryDex ATTeST Trial in all ages of A-T patients ATTeST Primary Endpoint (All Ages) in Intent to Treat (ITT) Population 3 -1.4 from 2 placebo to high dose (LSM; 1 P=0.077) 0 -1 Baseline Month 3 Month 6 Placebo Low Dose High Dose Note: mICARS = Modifie
Slide 11: EryDex treatment showed statistically significant effect in 6 to 9 year subgroup
EryDex treatment showed statistically significant EryDex ATTeST Trial effect in 6 to 9 year subgroup Primary population selected for Phase 3 NEAT clinical trial ATTeST 6-9 Year Subgroup, mICARS 6 4 -4.8 from placebo to high dose 2 (LSM; P=0.0016) 0 -2 Baseline Month 3 Month 6 Placebo Low Dose High D
Slide 12: EryDex consistent and statistically significant in 6 to 9 year subgroup across multiple endpoints
EryDex consistent and statistically significant in EryDex ATTeST Trial 6 to 9 year subgroup across multiple endpoints ATTeST ICARS Values in ITT Population EMA Endpoint FDA Endpoint ICARS CR ICARS LR mICARS CR mICARS LR RmICARS CR RmICARS LR 0 -1 -2 P=0.028 -3 P=0.009 P=0.019 -4 Phase 3 NEAT Primary
Slide 13: No clinically meaningful adverse events with EryDex
No clinically meaningful adverse events with EryDex, including EryDex ATTeST Trial those typically associated with chronic steroid treatment ATTeST: Initial Treatment Period ATTeST: Through Month 12 EDS-EP EDS-EP EDS-EP EDS-EP Non-switch Placebo Low Dose High Dose Low Dose High Dose Placebo (N=59) (
Slide 14: Phase 3 NEAT study design under SPA
Phase 3 NEAT study design under SPA Double-blind, randomized, placebo-controlled study over 6-month treatment period Plan to enroll first patient in global Phase 3 NEAT clinical trial of EryDex in second quarter 2024 Plan to enroll approximately 86 A-T patients ranging in age from 6 to 9 years-old U
Slide 15: EryDex attractive commercial and rapid expansion potential
EryDex attractive commercial and rapid expansion potential EryDex for A-T Approximately 10,000 A-T patients suffering from rare and debilitating pediatric disease in U.S., U.K., and EU4 countries with no currently approved therapies First-to-market potential with attractive pricing comparables and n
Slide 16: Strong balance sheet with approximately $87.6 million in cash
Strong balance sheet with approximately $87.6 million in cash, cash equivalents, and short term investments as of June 30, 2023 (unaudited) Well-capitalized into 2026 with ability to fully Capital efficient development plan funds: fund EryDex expected • EryDex Phase 3 NEAT study and NDA submission,
Slide 17: Seasoned leadership team
Seasoned leadership team Guenter Janhofer, M.D., Ph.D. Dirk Thye, M.D. • 30+ years of healthcare industry experience in roles of increasing complexity and scope • 20+ years of experience in biotech company creation, R&D and executive leadership • Previously CMO at EryDel and CMO at BTG (acquired by
Slide 18: Key clinical and corporate milestones
Key clinical and corporate milestones Second half of 2023 2024 2025 Close acquisition of EryDel in third Enroll first patient in Phase 3 NEAT Phase 3 NEAT clinical trial topline results quarter 2023 clinical trial in second quarter 2024 Target EryDex NDA submission Target resolution of partial clini
Slide 19: Transformative acquisition with value-creating clinical milestones
Transformative acquisition with value-creating clinical milestones Phase 3 lead asset EryDex targets Ataxia-Telangiectasia (A-T) with no currently approved treatments and estimated $1+ billion peak sales opportunity EryDex designed for controlled, slow release of dexamethasone over several weeks wit
Quince Therapeutics — Merger or Acquisition (July 2023) on 6ix